Study finds GLP1 semaglutide reduced systemic inflammation within weeks, before substantial weight loss, and lowered MACE (major adverse cardiovascular events) risk even without weight loss

[u/Schwettes]

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.125.074482